Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
August 29, 2023 09:05 ET
|
Immune Therapeutics, Inc.
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a...
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
March 01, 2023 09:34 ET
|
Immune Therapeutics, Inc.
ORLANDO, March 01, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" or "IMUN"), a specialty pharmaceutical company involved in the acquisition, development and...
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
November 09, 2022 17:00 ET
|
Immune Therapeutics, Inc.
Orlando, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”) today announced that its Chief Executive Officer, President, and Director, Stephen...
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
September 27, 2022 14:57 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a specialty pharmaceutical company involved in the acquisition, development, and...
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes
August 25, 2022 13:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a pioneering pharmaceutical company involved in the acquisition, development, and...
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
August 04, 2022 13:19 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development, and...
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
July 22, 2022 16:26 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, July 22, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development and...
Immune Therapeutics, Inc. Announces Expansion of its Board of Directors
June 03, 2022 17:26 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla, June 03, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing...